Objectives To examine the first-year treatment of incident SLE.
Methods The Finnish nationwide register data on special reimbursement decisions for SLE medication costs was screened to identify the inception cohort of adult SLE patient years 2000-2007. The cohort was shared in 2-year time periods according to index date. The patients were linked to prescription register, which includes drugs purchased from pharmacies. Both registries are maintained by the Social Insurance Institution. The first-year treatment of incident SLE was evaluated.
Results A total of 566 subjects (87% females) were included in the incident cohort. Five percent of patients had not used any medicine and 80% had used some disease modifying anti-rheumatic drug (DMARD) during the first- year treatment. Prescriptions of mycophenolate mofetil as an initial treatment increased significantly throughout the time periods (2000-01, 2002-03, 2004-05 and 2006-07). Since year 2004 orally taken cyclophosphamide was not used in the first-year treatment of SLE.
Conclusions Mycophenolate mofetil had a significant increasing trend in treatment of incident SLE during the study time. During the follow-up use of hydroxychloroquine and disease modifying anti-rheumatic drugs (DMARDs) was stable.
Disclosure of Interest None declared